Table 1.

Clinical studies of BET inhibitors that include lung cancer patients, registered with the database of the United States National Library of Medicine at the National Institutes of Health.

Registration Identifier	Recruitment Status as of 8/2018	Aim	Responsible Party
2,259,114	Completed	A Dose-Finding Study of OTX105/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)	Oncoethix GmbH
3,266,159	Withdrawn	A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors	GlaxoSmithKline
2,698,176	Terminated	A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)	Merck Sharp & Dohme Corp.
2,959,437	Active, not recruiting	Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)	Incyte Corporation
2,391,480	Recruiting	A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer	AbbVie
1,587,703	Active, not recruiting	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers	GlaxoSmithKline
2,431,260	Completed	An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies	Incyte Corporation
2,711,137	Active, not recruiting	Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies	Incyte Corporation